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L~ . 
Substance PIs Not Involved in Primary and Secondary Erythermalgia 
Sir, 
Erythermalgia is a syndrome of bilateral symmetric burning 
and redness of. mainly, the lower extremities. Symptoms can 
be initiated by exercise or exposure to heat. while rest and 
cold bring relief (I). Primary erythermalgia usually arises in 
childhood as au incurable variant of painful red extremities in 
the absence of thrombocythemia or any other underlying 
disorder {2). Secondary erythermalgia usually develops at 
adult age in aS'Sociation with or without an apparent underlying 
disorder. In some cases treatment of the underlying disorder 
is difficult and therefore symptoms may persist throughout life 
(3). Secondary erythennalgia can arise as a side-effect of 
drugs. In those cases relief can be obtained by withdrawal of 
the causative drug. The pathogenesis of primary and secondary 
erythermalgia remains to be elucidated. A neurogenic aetiology 
or vasomotoric dysregulation has been suggested as a potential 
cause of erythermalgia. 
Vasoactive neuropeptides, such as substance P (SP). are 
released from peripheral terminals from sensory nerve endings 
in human skin and are involved in (neurogenic) inflammatory 
cutaneous reactions ( 4) . SP, when injected intradermally, 
elicits a triple response with local erythema. a rapidly spreading 
flare and a slowly developing wheal (5). The fact that erytherm-
algic attacks are precipitated by an increase in skin temperature 
has given rise to speculations that temperature triggers release 
of inflammatory and pain mediating substances in sensitive 
areas of predisposed patients (6) . In this respect SP might 
have a role in the pathogenesis of erythermalgia. Further, 
hope is fuelled by the fact that symptoms of secondary 
erythermalgia in one patient responded to topical application 
of capsaicin cream (7). Repeated application of capsaicin 
depletes the sensory neurons of SP and suppresses the flare 
response to SP (8) . Consequently, we investigated the immuno-
reactivity of SP in flu id from artificial blisters from healthy 
and pathological skin in patients with primary and secondary 
erythermalgia. 
PATIENTS AND METHODS 
Patients 
Six women and one man (age 28- 76 years). suffering from erythermal-
gia, were invited to take part in the study. A 28-year-old patient 
suffered from primary erythermalgia and 6 had secondary erythcrmal-
gia. The associated conditions were autoimmune disorder of undeter-
mined significance (I); hypertension ( I ); SjOgren's syndrome (2): 
unknown (2). Prior to the procedure all patients provoked their 
symptoms by putt ing their feet in warm water or by strenuous exercise. 
Artificial blisters 
Suction blisters were induced on the volar aspect of the erytherrnalgic 
forefoot of every patient ( 9). Control blisters were evoked on apparent 
healthy skin on the upper legs. The blister devices were connected to 
the central suction unit of the hospital. and after application the 
pressure within the cup was slowly increased to 200 rnmHg below the 
atmospheric pressure. Blisters of 8-10 mm developed 3-4 h after 
suction. Blister fluid was collected by aspiration with a thin needle 
and syringe. Samples were immediately frozen to - 70°C. 
Radioimmunoassay for SP 
The concentration of SP was determined by a commercially avail-
able radio immunoassay ( Eurodiagnostica AB, Malmo, Sweden). 
Polyclonal antibody against syntheuc SP 
Synthetic SP was radiolabelled wnh 1 ~I. z= 
measured in duplicate by nonequilibnum ;:<. a:c:===~ 
measurement of SP. I 00 J.ll blister fluid \\':!S cs:::t 
limit of this method is I 0 pg/ml P pmoll 
The study protocol was approved b> th~ M~ 
of the University Hospital Dijkzigt in R
Written informed consent was obtained from d 
RESULTS 
The SP concentration in blister fluid n~ 
skin in primary erythermaJgia was 316 ~­
in erythermalgic skin. In one patient l\T.h sa:o::::::.:;::>. 
algia the SP content in blister fl uid frac 
and healthy skin was elevated to Ill pg -
respectively. In all other patients w1th ~ 
the SP concentration in the sampl~ was 
detection. 
DISCUSSION 
The low concentration of SP in the blister e,.11d ~ 
that SP present in sensory nerve endings in the ~ do.:s 
diffuse in measurable amounts into the blister fimd. 
investigators using a similar design with a slllllldr ~ 
radioimmunoassay have detected increased SP in suction-
induced blisters in Jesional and control skin of patients with 
bullous pemphigoid and urticaria ( 10, I I ). Our suction time 
of 3- 4 h was considerably longer than that used in this study 
(75-90 min), which suggests that inadequate diffusion of cuta-
neous SP into blister fluid does not explain the low concentra-
tions. On the other hand, it is also possible that a suction time 
of 3-4 h is too long, allowing proteolytic enzymes to degrade 
SP. We provoked blisters on the volar aspect of the forefoot, 
since it was known that the SP concentration is the highest in 
fingers and toes, opposed to axilla and thigh ( 12) . 
It also remains possible that SP is of minor in1portance as 
an inflammatory mediator in the pathogenesis of erythermal-
gia. The concept of neurologic inflammation as a cause of 
erythennalgia nevertheless remains an attractive hypothesis. 
An increased local production of other vasoactive neuropep-
tides, such as neurokinin A and calcitonin-G-related-peptide 
(CGRP), could be responsible for symptoms in erythermalgia. 
Intradermal injection of CGRP leads to a prolonged increase 
in cutaneous blood flow and erythema, as seen in erythermal-
gia. Although SP is chemotactic for human T-lymphocytes, 
CGRP is more potent ( 13) . We have shown earlier that biopsy 
specimens from erythermalgic skin are characterized by a mild 
mononuclear infiltrate, which suggests involvement of these 
vasoactive molecules ( 19). The contribution of these peptides 
the pathogenesis of erythermalgia thus requires further investi-
gation, and in this respect immunoreactive staining of biopsy 
specimens might be helpful. 
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